POLIVY and Health Insurance Denials
On June 10th, 2019, the FDA granted accelerated approval to the use of POLIVY with a bendamustine and rituximab product (BR) as a treatment for patients suffering from diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in America. It was approved for patients that have either returned after two prior treatments or who’s condition is worsening.
Despite DLBCL lymphoma having a cure, POLIVY with BR provides a new option for people who have not responded to other treatments. The FDA indicates that about 30-40% of patients will face a relapse of DLBCL, therefore POLIVY with BR can successfully prevent these relapses from causing damage.
POLIVY is an antibody-drug conjugate, meaning it is an antibody conjoined with a chemotherapy drug. This enables it to target and destroy cancerous cells. POLIVY attaches to protein CD79b, a protein commonly found in B cells in people with lymphoma, therefore targeting that specific type of white blood cell. Once attached to the B cell, the chemotherapy drug is released into the cancerous cell.
POLIVY with BR achieved accelerated FDA approval after a successful drug trial involving 80 patients. In the trial, some patients were given POLIVY with BR, while others were treated with just BR. The results of the study showed that 40% of patients exhibited a complete response to POLIVY with BR compared to the 18% of patients who showed a complete response with just BR. In total, 25 patients responded either partially or completely to POLIVY with BR treatment. Of the 25, 16 of them experienced a state of remission from DLBCL for six months and 12 of them experienced it for 12 months. Thus showcasing the potential POLIVY with BR treatment has to suppress or cure a very dangerous disease in diffuse large B-cell lymphoma.
If your insurance company has denied or delayed access to POLIVY then contact us for a free case evaluation.
Meet Our Team
If Results Matter, Then Hire Us
Our Case Results
Relentlessly Tough, Relentlessly Personal
Scott began representing policyholders instead of insurance companies in 1999 and has consistently sought justice for his clients in ways other firms cannot. Scott is passionate about helping policyholders obtain treatments, coverage, and reimbursement from California insurance companies, including Aetna, Anthem Blue Cross, Blue Shield of California, Health Net, Kaiser Permanente UnitedHealthcare, and other companies providing insurance.
-
$17.3 Million
On April 30, 2019, a 39-year-old father was fatally injured when his Kia Optima collided with a disabled Los Angeles County Metropolitan Authority (LACMTA) bus on the I-10 freeway's express lane.
-
$14.9 Million
Cowart v. Anthem Blue Cross, et al. Anthem sued for misleading California individual plan members about the doctors in its networks for its ACA (“Obamacare”) plans in 2014.
-
$10 Million
General areas addressed: health insurance; treatment and procedure coverage; physician recommendations; critical organ, brain, cancer or spinal cord issues; and out of network coverage issues.
-
$9.29 Million
Arce v. Kaiser. Kaiser Permanente sued for denying ABA and speech therapy to children with Autism Spectrum Disorders.
-
$8.5 Million
General areas addressed: health insurance; treatment and procedure coverage; physician recommendations; critical organ, brain, cancer or spinal cord issues; and outside of network coverage issues.
